Establishing the Role of Tigecycline in an era of Antimicrobial Resistance

Jason J. Schafer; Debra A. Goff


Expert Rev Anti Infect Ther. 2008;6(5):557-567. 

In This Article

Regulatory Affairs

Tigecycline was approved in June 2005 by the FDA for the treatment of cSSIs and cIAIs in adult patients. Since that time, the drug has also been approved in many South American countries, including Argentina, Brazil and Colombia. In May 2006, the European Commission also granted its approval of tigecycline for use in cSSIs and cIAIs.[2]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.